TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05099133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is an antibody given by injection just under the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is an antibody given by injection just under the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is an antibody given by injection just under the skin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 138559 Placebo
Description: LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.
Study: NCT04614714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside chloride
Description: Nicotinamide riboside chloride 250 mg capsules, administered once per day (Day 1-7 or Day 11-17)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside chloride
Description: Nicotinamide riboside chloride 250 mg capsules, administered once per day (Day 1-7 or Day 11-17)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Maltodextrin placebo, administered once per day (Day 1-7 or Day 11-17)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Maltodextrin placebo, administered once per day (Day 1-7 or Day 11-17)
Study: NCT04949386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1226 (8%)
Description: S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in gas/aerosol/vapor form within a medical gas mixture containing 8% CO2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will delivered by inhalation of saline (0.9% NaCl) and Medical grade air.
Study: NCT06599138

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound-guided maxillary nerve block
Description: Suprazygomatic approach, ultrasound-guided infrazygomatic window, maxillary nerve block for injection of 2 - 5 ml of contrast

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound-guided maxillary nerve block
Description: Suprazygomatic approach, ultrasound-guided infrazygomatic window, maxillary nerve block for injection of 2 - 5 ml of contrast
Study: NCT06612827

Intervention type: OTHER
Intervention: organoid etablishment
Description: Prior to initiation of 1st-line therapy:~* Collection of an additional study-specific tumor sample for tumoroid analysis (1 fresh tumor sample)~* A blood test blood a for tumoroid realization and :~* Analysis of ex vivo tumoroid response to treatment and correlation with patient response in vivo~* Analysis of correlation between in vivo and ex vivo tumor characteristics~* Analysis of first- and second-line survival rates and overall survival
Study: NCT05626582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain delivery - learning only
Description: Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin just during the Day 1 learning period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain delivery - learning and retention
Description: Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin during the Day 1 learning period and again during the Day 2 retention period.
Study: NCT06679647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to a trained ChatGPT
Description: Participants will be invited to use a trained ChatGPT which answers questions related to seasonal influenza vaccination. The functions can be used repeatedly throughout the intervention period (4 weeks), and participants will be free to spend as much time as they want on such functions.
Study: NCT06679465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (Spiriva®)
Description: 2 puffs tiotropium prior to allergen challenge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 puffs placebo
Study: NCT06678230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Alibulin 1.4mg/m2, D1, 8; Every 3 weeks is a cycle; Androtinib 12mg, QD, po, applied for 14 days, stopped for 7 days, and every 3 weeks was a cycle.
Study: NCT06678802

Intervention type: OTHER
Intervention: Blood sampling
Description: blood sampling from peripheral vein

Intervention type: OTHER
Intervention: Blood sampling
Description: blood sampling from peripheral vein

Intervention type: OTHER
Intervention: Blood sampling
Description: blood sampling from peripheral vein
Study: NCT06678893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture Needle on an adhesive
Description: This study utilizes acupuncture needs on small adhesives which will be placed according to the 5NP NADA Auricular Acupuncture Protocol.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Adhesives
Description: For those randomized to the placebo arm, adhesives without needles will be placed according to the 5NP NADA Auricular Acupuncture Protocol placement
Study: NCT06677801

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Telitacicept 160mg
Description: Telitacicept 160mg weekly for 24 weeks, and peripheral subtypes of immune cells will be measured at week 0, 4, 12, and 24.
Study: NCT06679764

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior quadratus lumborum block technique (AQLB)
Description: AQLB performed in the lateral position. A low-frequency convex probe for the abdomen (2-5) MHz convex probe, (Siemens ACUSON X300 Ultrasound System) was placed horizontally above the iliac crest. On ultrasound, The psoas major was located on the ventral side of the transverse process, the erector spinae was located on the dorsal side of the transverse process, and the quadratus lumborum was located on the lateral side of the transverse process.~A 38-mm 22-gauge regional block needle was advanced in-plane from posterior to anterior directing the needle tip in the fascial plane between the psoas major and the quadratus lumborum that was confirmed by injecting 1 ml saline and watchingt the fluil fting the muscle while not distending any of the two muscles (hydro-localization). Then 30mL of local anaesthetic (29ml of 0.25% bupivacaine + 1 ml of dexamethasone (4mgs) was injected with observation of local anaesthesia spread in the fascial plane.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Group (PENG) block
Description: With the patients in supine position, A low-frequency convex probe (2-5 MHz) in was placed in a transverse plane over the anterior inferior iliac spine and then it was rotated 45 degrees in counter-clockwise direction to be aligned with the pubic ramus. In this view, the ilio-pubic eminence, iliopsoas muscle tendon, femoral nerve and vessels was observed. With in-plane approach, a 38-mm 22-gauge (22-G, 50-mm) regional block needle inserted in-plane, from lateral to medial to place the needle tip underneath the iliopsoas tendon, exactly between the ilipsoas fascia anteriorly and the pubic ramus posteriorly. Following negative resistance and aspiration tests, correct location of the needle tip was confirmed by injecting 1 ml saline. Then, 30mL of local anaesthetic (29ml of 0.25% bupivacaine+ 1ml of dexamethasone (4mgs) was injected while observing for adequate fluid spread.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Pataints received opioid analgesia with genaral anesthesia
Study: NCT06679049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micromotion intramedullary nail cohort
Description: use of at least 2 distal interlocking screws and the use of a minimum of 1 proximal tibial interlocking screw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard intramedullary nail cohort
Description: use of at least 2 distal interlocking screws and the use of a minimum of 1 proximal interlocking screw
Study: NCT06678477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D device
Description: Use 3D machine to generate the 3D image
Study: NCT05096052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galactomannan
Description: Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: A blinded matching placebo containing inert chemistry not able to recognise and bind to the galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
Study: NCT06041139

Intervention type: DIAGNOSTIC_TEST
Intervention: Defocus Curve
Description: Measurement of visual acuity performed from +1.00 to -4.00 in 0.50 diopter steps and with +0.25 and -0.25 added.

Intervention type: DIAGNOSTIC_TEST
Intervention: Defocus Curve
Description: Measurement of visual acuity performed from +1.00 to -4.00 in 0.50 diopter steps and with +0.25 and -0.25 added.

Intervention type: DIAGNOSTIC_TEST
Intervention: Halo and Glare testing
Description: Measurement to quantify degree of visual loss caused by either halo and/or glare.

Intervention type: DIAGNOSTIC_TEST
Intervention: Halo and Glare testing
Description: Measurement to quantify degree of visual loss caused by either halo and/or glare.

Intervention type: OTHER
Intervention: Patient Questionnaires
Description: Patients will complete a series of questionnaires to record self-reported visual disturbances, visual acuity satisfaction, level of spectacle independence and any issues with glare, halos, and/or starbursts.

Intervention type: OTHER
Intervention: Patient Questionnaires
Description: Patients will complete a series of questionnaires to record self-reported visual disturbances, visual acuity satisfaction, level of spectacle independence and any issues with glare, halos, and/or starbursts.
Study: NCT06526585

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audiobook
Description: Participants are instructed to be seated or lying down, and can keep eyes open or closed throughout the 10 minutes of listening to the audiobook during the 28 days. Participants are instructed to keep their eyes closed during the 2 MRI assessments.
Study: NCT06146101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IHL-42X Low Dose
Description: Softgel capsule
Study: NCT06427824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery)
Description: An educational program designed by geriatricians, surgeons, anesthesiologists and palliative care physicians to help people with bladder cancer who plan to receive a cystectomy learn strategies to improve their mobility, medication management, mental clarity/delirium and how they document important side effects or health issues after surgery.
Study: NCT05292703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participatory activity based on art and olfactory stimulation
Description: practicing art in a group under supervision, involving the participants directly in the creative process, allowing them to become co-authors. Participants will meet once a week for 4 weeks for a 2-hour workshop at the Institut Claude Pompidou in Nice in a dedicated space, A different theme will be offered each week. Each workshop will be led by the same artist who will propose creative activities to be carried out by the participants and each session will result in a creation that the participant will take away, bringing into play artistic skills and olfactory identification capacities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: practicing art virtually in conjunction with olfactory identification
Description: For the remote group, , they will receive the connection link to the internet application and an individual connection code.~The intervention is a participative activity based on art and olfactory stimulation which consists of practicing art virtually in conjunction with olfactory identification by following a dedicated program developed in partnership with the same artist involved in the workshops in presence, so that the virtual activities are very similar to those of the face-to-face workshop.~The artistic workshops will take place according to 4 themes with a different theme per week. Each workshop end with an original artistic creation received by email, bringing into play artistic skills and olfactory identification capacities. Each participant will connect once a week at their convenience during 4 weeks.
Study: NCT04913090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-5610 Tablet (for Part A)
Description: Tablet(s) administered orally once daily for 1 Day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match XZP-5610 Tablet (for Part A)
Description: Tablet(s) administered orally once daily for 1 Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-5610 Tablet (for Part B)
Description: Tablet(s) administered orally once daily for 14 Days
Study: NCT06146101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IHL-42X High Dose
Description: Softgel capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Softgel capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IHL-42X (Optimal Dose)
Description: Softgel capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: Softgel capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Softgel capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Softgel capsule
Study: NCT04913090

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match XZP-5610 Tablet (for Part B)
Description: Tablet(s) administered orally once daily for 14 Days
Study: NCT06484140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Navigation
Description: During hospitalization, participants will receive needs assessment, and one-on-one cost-related health education with a material booklet. Resource and service referral will be delivered face-to-face or by phone when the navigator identifies unaddressed problems. Within three months after discharge, participants will receive monthly follow-up phone calls and personalized counseling via WeChat.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive usual oncology care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support.
Study: NCT06390488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous medial plantar nerve stimulation (T-MPNS)
Description: T-MPNS will be conducted unilaterally in the supine position using the electrotherapy device with surface electrodes. Two round self-adhesive electrodes will be positioned, with the negative electrode near the metatarsal-phalangeal joint of the great toe on the medial aspect of the foot and the positive electrode approximately 2 cm inferior-posterior to the medial malleolus (in front of the Medio-Malleolar-Calcaneal axis). Channel 1 will provide active stimulation, while channel 2 will remain inactive.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous medial plantar nerve stimulation (T-MPNS)
Description: Sham T-MPNS group will be stimulated using the same electrotherapy device, with patients positioned identically and electrodes placed in the same positions as in the T-MPNS group. The current characteristics (pulse frequency 20 Hz and pulse width 200 ms) will also remain consistent across both channels. The second channel of the stimulation device will be designated as the channel connected to the patient but without delivering stimulation.
Study: NCT06505837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy
Description: The combination therapy of JS001sc and pemetrexed/platinum lasted for 4 cycles, after which subjects who did not progress continued to receive JS001sc and pemetrexed maintenance therapy, and the cumulative treatment of JS001sc did not exceed 35 cycles (Each cycle is 21 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy
Description: The combination therapy of JS001 and pemetrexed/platinum lasted for 4 cycles, after which subjects who did not progress continued to receive JS001 and pemetrexed maintenance therapy, and the cumulative treatment of JS001 did not exceed 35 cycles (Each cycle is 21 days).
Study: NCT04913649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose 100 MG/ML
Description: Postoperative treatment with a single dose IVI (ferric derisomaltose), with a dose of 20mg/kg in approximately 60 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Postoperative treatment with a single dose NaCl 0.9% in approximately 60 minutes.
Study: NCT06056050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)
Description: 1 dose of Tdcp vaccine (0.5ml) on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)
Description: 1 dose of Tdcp vaccine (0.5ml) on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)
Description: 1 dose of Tdcp vaccine (0.5ml) on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）
Description: 1 dose of PPV23 vaccine (0.5ml) on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）
Description: 1 dose of PPV23 vaccine (0.5ml) on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)
Description: 1 dose of DT vaccine (0.5ml) on Day 0
Study: NCT05892913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slow dose preemptive Atropine
Description: it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: For sympathetic blockade (SBP\<90) developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine was used and repeated if necessary.
Study: NCT04327596

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter
Description: Ablation of AF is standard of care in the management of patients with paroxysmal or persistent AF. The most common triggers initiating AF arise from pulmonary veins (PV) and successful electrical isolation of PV's can significantly reduce the burden of AF. Therefore, the main objective in patients undergoing ablation of AF is to achieve PV isolation.
Study: NCT04831775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory, Attention, and Problem Solving Skills for Diabetes
Description: The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice and will be held over 8 weeks. The classes will be taught by a GRA. Classes 1 \& 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 \& 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. Each online class will follow the same format: (1) introduction/revisiting content from the previous class; (2) review of progress on computer exercises; (3) practicing cognitive strategies in class; and (4) a weekly topic. The GRA will also prescribe exercises for the following weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Games
Description: The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Participants will only need a computer, smart phone, or tablet with Internet access to securely log onto the website. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on.
Study: NCT06030687

Intervention type: OTHER
Intervention: Ad libitum data collection
Description: Food purchase, prep, eat and toss data
Study: NCT06395311

Intervention type: OTHER
Intervention: COPD psychological well-being assessment
Description: Patients will complete the following questionnaires: Hospital Anxiety and Depression Scale (HADS), COPD Assessment Test (CAT), State Shame and Guilt Scale (SSGS), Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE), Brief Fear of Negative Evaluation Scale (BFNE), Self-Compassion Scale Short Form (SCS-SF). Dyspnea will be evaluated with the mMRC scale, and functional capacity will be assessed with the six-minute walking test (6MWT).
Study: NCT06427824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery)
Description: An educational program designed by geriatricians, surgeons, anesthesiologists and palliative care physicians to help people with bladder cancer who plan to receive a cystectomy learn strategies to improve their mobility, medication management, mental clarity/delirium and how they document important side effects or health issues after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric Service/ Discharge Planning
Description: A geriatric team will meet with participants after surgery to help them reinforce the strategies they learned in the education video sessions. As part of a geriatric service, this team will also help participants plan/coordinate their discharge from the hospital after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: These questionnaires will ask about the participants' mobility, frailty, quality of life and additional health/risk factors before and after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: These questionnaires will ask about the participants' mobility, frailty, quality of life and additional health/risk factors before and after surgery.
Study: NCT05391529

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Semi structured patient interview via telephone

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Semi structured patient interview via telephone